Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use

by Zacks Equity Research

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

by Zacks Equity Research

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

by Zacks Equity Research

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.

Best Momentum Stocks to Buy for December 2nd

by Zacks Equity Research

CCRN, ENDP, GOOS, and TITN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 2, 2021.

AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.

Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.

ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study

by Zacks Equity Research

ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

Do Options Traders Know Something About Endo International (ENDP) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to for Endo International (ENDP) stock based on the movements in the options market lately.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Endo (ENDP)

by Zacks Equity Research

Endo (ENDP) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study

by Zacks Equity Research

PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.

ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos

by Zacks Equity Research

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3

by Zacks Equity Research

Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.

ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top

by Zacks Equity Research

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

Perrigo (PRGO) Misses on Q3 Earnings, Lowers Earnings View

by Zacks Equity Research

Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.

Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Zacks.com featured highlights include: Endo International, SM Energy, CBRE Group, ON Semiconductor and Penske Automotive

by Zacks Equity Research

Zacks.com featured highlights include: Endo International, SM Energy, CBRE Group, ON Semiconductor and Penske Automotive

ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Endo (ENDP)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Endo (ENDP) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Nilanjan Choudhury headshot

5 Stocks Investors Must Buy for Relative Price Strength

by Nilanjan Choudhury

Endo International (ENDP), SM Energy (SM), CBRE Group (CBRE), ON Semiconductor (ON) and Penske Automotive Group (PAG) are five stocks with explosive relative price strength.

Are You Looking for a Top Momentum Pick? Why Endo International (ENDP) is a Great Choice

by Zacks Equity Research

Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Endo International (ENDP) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View

by Zacks Equity Research

Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.

Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 73.91% and 15.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3

by Kanishka Das

Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.